Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SCG3 antisense RNA 1 (SCG3-AS1) is a long non-coding RNA that is transcribed antisense to the Secretogranin III (SCG3) gene. Antisense lncRNAs often regulate the expression of their partner sense genes or nearby loci through mechanisms such as chromatin remodeling, transcriptional interference, or RNA:RNA interactions [3][4]. While antisense lncRNAs in general are implicated in gene expression regulation and have context-dependent roles in cancer, proliferation, apoptosis, and development, there is currently limited data in the literature specifying the functional or disease role of SCG3-AS1 itself [4]. SCG3-AS1 is not a canonical therapeutic target (such as a receptor or enzyme), nor is it currently targeted by drugs or validated as a biomarker. The associated SCG3 gene encodes Secretogranin III, a granin family protein important in neuroendocrine secretion and tumor diagnostics, but SCG3-AS1 does not code for a protein and has principally regulatory potential [2][3][4]. If you require information about the associated protein Secretogranin III (SCG3), which is a protein-coding gene with emerging disease relevance [2][5], that can be provided separately.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SCG3 antisense RNA 1 (SCG3-AS1).